Search

Your search keyword '"Chavarot N"' showing total 38 results

Search Constraints

Start Over You searched for: Author "Chavarot N" Remove constraint Author: "Chavarot N"
38 results on '"Chavarot N"'

Search Results

1. Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

2. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

Catalog

Books, media, physical & digital resources

3. Basophiles et auto-immunité

7. Heart failure associated with socioeconomic status stronger in younger patients: a French nationwide cohort study.

8. Increased Risk of Invasive Aspergillosis in Immunocompromised Patients With Persistent SARS-CoV-2 Viral Shedding >8 Weeks, Retrospective Case-control Study.

9. CMV-related anterior and intermediate uveitis in a kidney transplant recipient treated with belatacept.

10. Immunogenicity of Anti-SARS-CoV-2 Vaccination After Kidney Transplantation in Kidney Transplant Recipients Vaccinated Before Transplantation.

11. Stiripentol and Lumasiran as a Rescue Therapy for Oxalate Nephropathy Recurrence After Kidney Transplantation in an Adult Patient With Primary Hyperoxaluria Type 1.

12. Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients.

13. De novo posttransplant membranous nephropathy following BNT162b2 mRNA COVID-19 vaccine in a kidney transplant recipient.

14. Severe relapse of SARS-CoV-2 infection in a kidney transplant recipient with negative nasopharyngeal SARS-CoV-2 RT-PCR after rituximab.

15. Early treatment with sotrovimab monoclonal antibody in kidney transplant recipients with Omicron infection.

16. Weak antibody response to three doses of mRNA vaccine in kidney transplant recipients treated with belatacept.

17. Clinical Utility of Biochemical Markers for the Prediction of COVID-19-Related Mortality in Kidney Transplant Recipients.

18. Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated With Belatacept.

19. Occurrence of severe COVID-19 in vaccinated transplant patients.

20. [COVID-19 vaccination in dialysis and kidney transplant patients].

22. Increased incidence and unusual presentations of CMV disease in kidney transplant recipients after conversion to belatacept.

23. Is COVID-19 infection more severe in kidney transplant recipients?

25. Ig-responsive relapsing inflammatory syndrome following COVID-19 in a kidney transplant recipient.

26. COVID-19 severity in kidney transplant recipients is similar to nontransplant patients with similar comorbidities.

27. Decline and loss of anti-SARS-CoV-2 antibodies in kidney transplant recipients in the 6 months following SARS-CoV-2 infection.

29. An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants.

30. Opportunistic Infections and Efficacy Following Conversion to Belatacept-Based Therapy after Kidney Transplantation: A French Multicenter Cohort.

31. Opportunistic infections after conversion to belatacept in kidney transplantation.

33. CD89 Is a Potent Innate Receptor for Bacteria and Mediates Host Protection from Sepsis.

34. Responsiveness to Change of 5-point MRC scale, Endurance and Functional Evaluation for Assessing Myositis in Daily Clinical Practice.

35. Cutis laxa for diagnosis of γ1-heavy-chain deposition disease: Report of four cases.

36. Prostaglandin D 2 amplifies lupus disease through basophil accumulation in lymphoid organs.

37. Rituximab alone as induction therapy for membranous lupus nephritis: A multicenter retrospective study.

38. Is lymphocytic sialadenitis IgG4-related?